Cover Image
市場調查報告書

肝血管瘤:全球臨床實驗檢討

Hemangiomas Global Clinical Trials Review, H1, 2014

出版商 GlobalData 商品編碼 296488
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
Back to Top
肝血管瘤:全球臨床實驗檢討 Hemangiomas Global Clinical Trials Review, H1, 2014
出版日期: 2014年02月19日 內容資訊: 英文 76 Pages
簡介

本報告提供全球肝血管瘤治療藥臨床實驗相關調查,提供各地區的臨床實驗數資料,實驗階段,實驗狀況及各類型贊助企業的臨床實驗資料,為您概述為以下內容。

目錄

簡介

  • 肝血管瘤
  • 報告指南

臨床實驗: 各地區

  • 臨床實驗及被實驗人數: 各國
    • 亞太地區:前五名國家
    • 歐洲:前五名國家
    • 北美:前幾名國家
    • 中東·非洲:前幾名國家
    • 中南美:前幾名國家

臨床實驗 G7各國

臨床實驗 G7各國:各臨床實驗狀態

臨床實驗 E7各國

臨床實驗 E7各國:各臨床實驗狀態

各階段臨床實驗:

  • 進行中的臨床實驗:各階段

各臨床實驗狀態臨床實驗:

一定期間內募集的實驗對象

贊助商各類型臨床實驗

有力的贊助商

  • 主要的參與臨床實驗企業

潛力治療藥物

臨床實驗簡介

  • 臨床實驗概要: 主要企業
    • Laboratoires Pierre Fabre SA
    • MethylGene Inc
    • Maruho Co., Ltd
    • InfectoPharm Arzneimittel und Consilium GmbH
  • 臨床實驗概要: 主要大學 / 研究機關 / 醫院
    • Medical College of Wisconsin
    • The University of New Mexico
    • The Hospital for Sick Children
    • 慶應大學
    • The Ohio State University
    • Southwest Hospital, China
    • Oregon Health and Science University
    • National Institute of Neurological Disorders and Stroke
    • Eastern Hepatobiliary Surgery Hospital
    • National Cancer Institute

5個主要的臨床實驗簡介

附錄

圖表

目錄
Product Code: GDHC1982CTIDB

GlobalData's clinical trial report, "Hemangiomas Global Clinical Trials Review, H1, 2014" provides data on the Hemangiomas clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hemangiomas. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hemangiomas. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Hemangiomas
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Hemangiomas to Dermatology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Hemangiomas to Dermatology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Hemangiomas
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Hemangiomas Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Laboratoires Pierre Fabre SA
      • Clinical Trial Overview of Laboratoires Pierre Fabre SA
      • MethylGene Inc.
      • Clinical Trial Overview of MethylGene Inc.
      • Maruho Co., Ltd.
      • Clinical Trial Overview of Maruho Co., Ltd.
      • InfectoPharm Arzneimittel und Consilium GmbH
      • Clinical Trial Overview of InfectoPharm Arzneimittel und Consilium GmbH
    • Clinical Trial Overview of Top Institutes / Government
      • Medical College of Wisconsin
      • Clinical Trial Overview of Medical College of Wisconsin
      • The University of New Mexico
      • Clinical Trial Overview of The University of New Mexico
      • The Hospital for Sick Children
      • Clinical Trial Overview of The Hospital for Sick Children
      • Keio University
      • Clinical Trial Overview of Keio University
      • The Ohio State University
      • Clinical Trial Overview of The Ohio State University
      • Southwest Hospital, China
      • Clinical Trial Overview of Southwest Hospital, China
      • Oregon Health and Science University
      • Clinical Trial Overview of Oregon Health and Science University
      • National Institute of Neurological Disorders and Stroke
      • Clinical Trial Overview of National Institute of Neurological Disorders and Stroke
      • Eastern Hepatobiliary Surgery Hospital
      • Clinical Trial Overview of Eastern Hepatobiliary Surgery Hospital
      • National Cancer Institute
      • Clinical Trial Overview of National Cancer Institute
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Hemangiomas Therapeutics, Global, Clinical Trials by Region, 2014*
  • Hemangiomas Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Hemangiomas Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Hemangiomas Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Hemangiomas Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Hemangiomas Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Hemangiomas Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014*
  • Hemangiomas Therapeutics Clinical Trials, Central and South America, Top Countries, 2014*
  • Proportion of Hemangiomas to Dermatology Clinical Trials, G7 Countries (%), 2014*
  • Hemangiomas Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Hemangiomas Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Hemangiomas to Dermatology Clinical Trials, E7 Countries (%), 2014*
  • Hemangiomas Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Hemangiomas Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Hemangiomas Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Hemangiomas Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Hemangiomas Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Hemangiomas Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Hemangiomas Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Hemangiomas Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Hemangiomas Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Hemangiomas Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Hemangiomas Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Hemangiomas Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Hemangiomas Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Hemangiomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Laboratoires Pierre Fabre SA, 2014*
  • Hemangiomas Therapeutics Clinical Trials Market, Global, Clinical Trials by MethylGene Inc., 2014*
  • Hemangiomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Maruho Co., Ltd., 2014*
  • Hemangiomas Therapeutics Clinical Trials Market, Global, Clinical Trials by InfectoPharm Arzneimittel und Consilium GmbH, 2014*
  • Hemangiomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical College of Wisconsin, 2014*
  • Hemangiomas Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of New Mexico, 2014*
  • Hemangiomas Therapeutics Clinical Trials Market, Global, Clinical Trials by The Hospital for Sick Children, 2014*
  • Hemangiomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Keio University, 2014*
  • Hemangiomas Therapeutics Clinical Trials Market, Global, Clinical Trials by The Ohio State University, 2014*
  • Hemangiomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Southwest Hospital, China, 2014*
  • Hemangiomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Oregon Health and Science University, 2014*
  • Hemangiomas Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Neurological Disorders and Stroke, 2014*
  • Hemangiomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Eastern Hepatobiliary Surgery Hospital, 2014*
  • Hemangiomas Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014*

List of Figures

  • Hemangiomas Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Hemangiomas Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Hemangiomas Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Hemangiomas Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Hemangiomas Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Hemangiomas Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Hemangiomas Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014*
  • Proportion of Hemangiomas to Dermatology Clinical Trials, G7 Countries (%), 2014*
  • Hemangiomas Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Hemangiomas Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Hemangiomas to Dermatology Clinical Trials, E7 Countries (%), 2014*
  • Hemangiomas Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Hemangiomas Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Hemangiomas Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Hemangiomas Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Hemangiomas Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Hemangiomas Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Hemangiomas Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Hemangiomas Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Hemangiomas Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Hemangiomas Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top